Researchers have successfully engineered CAR-T cells directly inside the bodies of patients with autoimmune diseases, bypassing the complex and expensive external manufacturing processes typically required for cellular therapies.
In Vivo CAR-T Generation and Clinical Outcomes
Traditional CAR-T cell therapies require extracting a patient’s T cells, modifying them in a laboratory setting using viral vectors to target specific antigens, and then reinfusing the multiplied cells back into the patient. For this clinical trial, the research team utilized an in vivo strategy by injecting a lentiviral vector directly into patients. This vector delivered genetic instructions straight to the T cells inside the body, programming them to recognize and suppress rogue B cells that mistakenly attack healthy tissue, such as the myelin sheath protecting nerve fibers in multiple sclerosis patients.
Following a single injection of the gene-delivery vector and a six-month follow-up period, patient evaluations showed a decrease in both rogue B cells and the antibodies they secrete.
Safety Profile and Immune System Reset
The clinical trial tracked manageable adverse events, noting that mild inflammatory reactions typically resolved within two weeks. Three participants experienced mild-to-moderate white blood cell count reductions that later normalized. As the engineered CAR-T cells cleared out the harmful B cells, populations of healthy B cells that do not attack normal tissue rebounded, which researchers noted indicates a functional reset of the immune system.
Prof. David Simon of Charité – Universitätsmedizin Berlin described the results as a highly encouraging proof-of-concept for in vivo CAR-T cell therapy, pointing out its potential advantages in production speed and lower costs compared to ex vivo methods.
Addressing Cost and Production Barriers
Standard CAR-T treatments, which have gained regulatory approvals from agencies such as the U.S. Food and Drug Administration since 2017 primarily for hematological malignancies like blood cancers, often carry average costs of $500,000 due to intricate facility requirements and lengthy handling timelines. By generating the therapeutic cells inside the patient, the new method functions similarly to establishing a manufacturing site directly at the target location, which could significantly cut production and logistics expenditures.
The broader scientific community continues to explore alternative delivery mechanisms for in vivo cellular reprogramming. These ongoing advancements aim to broaden the reach of cellular immunotherapy from oncology into challenging chronic autoimmune indications.
Related reading